Clinical Trial Update: Metronomic Cyclophosphamide With Pembrolizumab in Checkpoint Inhibitor Refractory Melanoma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating metronomic cyclophosphamide with pembrolizumab for checkpoint inhibitor-refractory melanoma; study is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Cytoxan (cyclophosphamide)
• KEYTRUDA (PEMBROLIZUMAB)

Snippet

Sponsor: University of California, Irvine | Conditions: Melanoma, Melanoma Stage III | Phase 2 | Status: RECRUITING